TABLE 1.
Characteristics of NEOSTAR and ICON Patients
| Variables | NEOSTAR |
ICON |
P value | ||
|---|---|---|---|---|---|
| Arm A nivolumab (n = 21) | Arm B nivolumab with ipilimumab (n = 16) | Chemotherapy (n = 34) | Upfront resection (n = 107) | ||
| Age, y | 66 (58-83) | 66 (43-76) | 63 (42-81) | 69 (38-85) | .09 |
|
| |||||
| Male sex | 14 (67) | 10 (63) | 16 (47) | 48 (45) | .22 |
|
| |||||
| Smoking status | .01 | ||||
| Current smoker | 4 (19) | 5 (31) | 0 | 7 (7) | |
| Former smoker | 12 (57) | 9 (56) | 29 (85) | 81 (76) | |
| Never smoker | 5 (24) | 2 (13) | 5 (15) | 19 (18) | |
|
| |||||
| Resection approach | .20 | ||||
| Open | 15 (71) | 12 (75) | 28 (82) | 85 (79) | |
| VATS | 5 (24) | 2 (13) | 2 (6) | 18 (17) | |
| RATS | 1 (5) | 2 (13) | 4 (12) | 4 (4) | |
|
| |||||
| Conversion from VATS or RATS to open | 1 (17) | 1 (25) | 2 (33) | 0 | .03 |
|
| |||||
| Resection type | .02 | ||||
| Sublobar | 2 (10) | 0 | 0 | 5 (5) | |
| Lobectomy | 15 (71) | 15 (94) | 20 (59) | 88 (82) | |
| Bilobectomy | 0 | 1 (6) | 5 (15) | 3 (3) | |
| Sleeve lobectomy | 2 (10) | 0 | 2 (6) | 1 (1) | |
| Pneumonectomy | 2 (10) | 0 | 7 (21) | 10 (9) | |
|
| |||||
| Histology | .01 | ||||
| Adenocarcinoma | 11 (52) | 11 (69) | 20 (59) | 78 (73) | |
| SCC/adenosquamous | 10 (48) | 5 (31) | 10 (29) | 29 (27) | |
| Large cell | 0 | 0 | 4 (12) | 0 | |
|
| |||||
| Clinical stage | <.01 | ||||
| I | 11 (52) | 11 (69) | 1 (3) | 64 (60) | |
| II | 6 (29) | 3 (19) | 13 (38) | 38 (36) | |
| III | 4 (19) | 2 (13) | 20 (59) | 5 (5) | |
Data are n(%) or median (range). NEOSTAR, Nivolumab With or Without Ipilimumab in Treating Patients With Previously Untreated Stage I-IIIA Non-Small Cell Lung Cancer; ICON, The Immunogenomic Profiling of NSCLC; VATS, video-assisted thoracoscopic surgery; RATS, robot-assisted thoracic surgery; SCC, squamous cell carcinoma.